Non-surgical back of eye disease treatment trialled
The Phase III trial of microplasmin for the treatment of back of the eye disease has been initiated, according to a statement from ThromboGenics NV, the developer of microplasmin.
The Phase III trial of microplasmin for the treatment of back of the eye disease has been initiated, according to a statement from ThromboGenics NV, the developer of microplasmin.
The multicentre MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment) trial will be conducted in Europe and North America, and will evaluate microplasmin versus placebo as an intravitreal treatment of patients with focal vitreomacular adhesion. Approximately 80 centres will enrol approximately 320 patients each, and the primary endpoint is resolution of vitreomacular adhesion at one month.
The studies, which were initiated following promising Phase II results, are planned to be completed by the end of 2010.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
